Isn't revenue yet to really start? I mean, a majority of their product isn't implemented until later this year. So to say their model isn't working seems a bit harsh.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025